Hormone receptor status should be defined in all newly diagnosed, invasive breast carcinomas as well as in recurrences, in order to determine patient eligibility for hormone therapy, which provides substantial survival benefit for patients with hormone-positive tumors. This evidence concerns the gene NR4A1 and invasive breast carcinoma.